Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12
Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2015-02, Vol.135 (2), p.AB127-AB127 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | AB127 |
|---|---|
| container_issue | 2 |
| container_start_page | AB127 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 135 |
| creator | Rosén, Karin, MD, PhD Khalil, Sam, PhD Balp, Maria-Magdalena, MD Maurer, Marcus, MD |
| description | Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies. |
| doi_str_mv | 10.1016/j.jaci.2014.12.1348 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1660396064</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674914031297</els_id><sourcerecordid>1660396064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2558-17e9892aa8b6d488c2c5e0d30a15f89745ab2778d24852d82e62f202210917343</originalsourceid><addsrcrecordid>eNpdUl2LEzEUHUTBuvoLfLngS_vQNsl8ZXwQul11BwrbWouPIc3c2aY7M-km6er4r_0HZqgiCBdCLufmnHtyougtJTNKaDY_zo5S6RkjNJlRNqNxwp9FI0qKfJpxlj6PRoQUdJrlSfEyeuXckYR7zItR9OuulY3-eW7lHsr2ZM0TOticQ8_3YGpY6RphvDGrCegO1tJr7LyD79of4AvWVipvbA_LgzWdVrA9mc7LDs3ZzctKm5P0h9DeWa-VtFrCeLndzZflbgILF8phqAque_AHhBu0rfSmMff9hfivkLKr8AeMb1abcvIeFrA2zk9vjYJFJ5veaTdIXaNVQVzQIrt7hNqaFq6lw0Z3CN7AN8QHoOx19KKWjcM3f86raPfp49fl7XR197lcLlZTxdKUT2mOBS-YlHyfVQnniqkUSRUTSdOaF3mSyj3Lc16xhKes4gwzVjPCWHCd5nESX0Xjy7vB1MczOi9a7RQ2zcUeQbOMxEVGsgH67j_o0ZxtWG1ApYElTigJqPiCUtY4Z7EWJ6tbaXtBiRhiII5iiIEYYiAoE0MMwtSHyxSGXZ80WqGCIeE3mgfs0f0jEo4JIrZDUIac0ITElBV5_BuW_brd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652773410</pqid></control><display><type>article</type><title>Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Rosén, Karin, MD, PhD ; Khalil, Sam, PhD ; Balp, Maria-Magdalena, MD ; Maurer, Marcus, MD</creator><creatorcontrib>Rosén, Karin, MD, PhD ; Khalil, Sam, PhD ; Balp, Maria-Magdalena, MD ; Maurer, Marcus, MD</creatorcontrib><description>Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2014.12.1348</identifier><language>eng</language><publisher>St. Louis: Elsevier Limited</publisher><subject>Allergy and Immunology ; Personal relationships ; Quality of life</subject><ispartof>Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB127-AB127</ispartof><rights>Copyright Elsevier Limited Feb 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2558-17e9892aa8b6d488c2c5e0d30a15f89745ab2778d24852d82e62f202210917343</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids></links><search><creatorcontrib>Rosén, Karin, MD, PhD</creatorcontrib><creatorcontrib>Khalil, Sam, PhD</creatorcontrib><creatorcontrib>Balp, Maria-Magdalena, MD</creatorcontrib><creatorcontrib>Maurer, Marcus, MD</creatorcontrib><title>Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12</title><title>Journal of allergy and clinical immunology</title><description>Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.</description><subject>Allergy and Immunology</subject><subject>Personal relationships</subject><subject>Quality of life</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdUl2LEzEUHUTBuvoLfLngS_vQNsl8ZXwQul11BwrbWouPIc3c2aY7M-km6er4r_0HZqgiCBdCLufmnHtyougtJTNKaDY_zo5S6RkjNJlRNqNxwp9FI0qKfJpxlj6PRoQUdJrlSfEyeuXckYR7zItR9OuulY3-eW7lHsr2ZM0TOticQ8_3YGpY6RphvDGrCegO1tJr7LyD79of4AvWVipvbA_LgzWdVrA9mc7LDs3ZzctKm5P0h9DeWa-VtFrCeLndzZflbgILF8phqAque_AHhBu0rfSmMff9hfivkLKr8AeMb1abcvIeFrA2zk9vjYJFJ5veaTdIXaNVQVzQIrt7hNqaFq6lw0Z3CN7AN8QHoOx19KKWjcM3f86raPfp49fl7XR197lcLlZTxdKUT2mOBS-YlHyfVQnniqkUSRUTSdOaF3mSyj3Lc16xhKes4gwzVjPCWHCd5nESX0Xjy7vB1MczOi9a7RQ2zcUeQbOMxEVGsgH67j_o0ZxtWG1ApYElTigJqPiCUtY4Z7EWJ6tbaXtBiRhiII5iiIEYYiAoE0MMwtSHyxSGXZ80WqGCIeE3mgfs0f0jEo4JIrZDUIac0ITElBV5_BuW_brd</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Rosén, Karin, MD, PhD</creator><creator>Khalil, Sam, PhD</creator><creator>Balp, Maria-Magdalena, MD</creator><creator>Maurer, Marcus, MD</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20150201</creationdate><title>Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12</title><author>Rosén, Karin, MD, PhD ; Khalil, Sam, PhD ; Balp, Maria-Magdalena, MD ; Maurer, Marcus, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2558-17e9892aa8b6d488c2c5e0d30a15f89745ab2778d24852d82e62f202210917343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allergy and Immunology</topic><topic>Personal relationships</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosén, Karin, MD, PhD</creatorcontrib><creatorcontrib>Khalil, Sam, PhD</creatorcontrib><creatorcontrib>Balp, Maria-Magdalena, MD</creatorcontrib><creatorcontrib>Maurer, Marcus, MD</creatorcontrib><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosén, Karin, MD, PhD</au><au>Khalil, Sam, PhD</au><au>Balp, Maria-Magdalena, MD</au><au>Maurer, Marcus, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2015-02-01</date><risdate>2015</risdate><volume>135</volume><issue>2</issue><spage>AB127</spage><epage>AB127</epage><pages>AB127-AB127</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.</abstract><cop>St. Louis</cop><pub>Elsevier Limited</pub><doi>10.1016/j.jaci.2014.12.1348</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB127-AB127 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1660396064 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier) |
| subjects | Allergy and Immunology Personal relationships Quality of life |
| title | Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T21%3A31%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omalizumab%20Improves%20Quality%20of%20Life%20(QoL)%20in%20Patients%20with%20Refractory%20Chronic%20Spontaneous/Idiopathic%20Urticaria%20(CSU/CIU)%20As%20Assessed%20By%20the%20Dermatology%20Life%20Quality%20Index%20(DLQI):%20A%20Post-Hoc%20Analysis%20of%20Percent%20Change%20from%20Baseline%20to%20Week%2012&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Ros%C3%A9n,%20Karin,%20MD,%20PhD&rft.date=2015-02-01&rft.volume=135&rft.issue=2&rft.spage=AB127&rft.epage=AB127&rft.pages=AB127-AB127&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2014.12.1348&rft_dat=%3Cproquest_cross%3E1660396064%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652773410&rft_id=info:pmid/&rft_els_id=1_s2_0_S0091674914031297&rfr_iscdi=true |